InFlectis Gains Patent Rights to Potential Myelin Therapy for CMT

InFlectis Gains Patent Rights to Potential Myelin Therapy for CMT

297519

InFlectis Gains Patent Rights to Potential Myelin Therapy for CMT

InFlectis BioScience and the University of Chicago have entered into an agreement that grants InFlectis exclusive patent rights to use a family of small molecules as potential treatments for demyelinating disorders that include Charcot-Marie-Tooth disease (CMT). Specifically, the license covers the use of IFB-088 and IFB-048, InFlectis’ lead compounds, for the treatment of CMT and multiple sclerosis (MS), according to a press release. Notably, IFB-088 is entering Phase 2 clinical trials in CMT and amyotrophic…

You must be logged in to read/download the full post.